Literature DB >> 8203787

Mediators involved in inflammation: effects of Daflon 500 mg on their release.

T Jean1, M C Bodinier.   

Abstract

Each step of an inflammatory reaction is triggered by one or several chemical or biological mediators such as arachidonic acid derivatives (prostaglandins [PG], leukotrienes [LT], or thromboxanes [TX]), vasoactive amines (histamine or serotonin), and oxygen free radicals (superoxide ion, O2-, or hydrogen peroxide, H2O2). In perivenous inflammation, these mediators play a prominent role in favoring vasodilatation (histamine), increasing membrane permeability (PGE2, histamine, free radicals) and providing a chemotactic signal for specialized cells, ie, neutrophil polynuclears, macrophages, lymphocytes (LTB4, free radicals). The antiinflammatory effects of Daflon 500 mg,* a micronized purified flavonoid fraction (90% diosmin, 10% hesperidin), were studied in different in vivo and in vitro models. In a model of inflammatory granuloma in the rat, Daflon 500 mg (100 mg/kg, orally) reduced edema formation and inhibited the synthesis for PGE2 (78.5%), PGF2 alpha (45.2%) and TXB2 (59.5%) (Damon et al, Arzneim-Forsch/Drug Res 37:1149-1153, 1987). Intravenous injection of Daflon 500 mg (25 and 50 mg/kg) reduced the hyperglycemia induced by injection of alloxan in rat. This effect of Daflon 500 mg was linked to its ability to scavenge active oxygen radicals, demonstrated in vitro using human neutrophils (Lonchampt et al, Arzneim-forsch/Drug Res 39:882-885, 1989) or mouse peritoneal macrophages (Bodinier et al, manuscript in preparation) stimulated by zymosan. The free radical scavenger effect of Daflon 500 mg is observed at concentrations ranging from 10(-7) M to 10(-4) M, with half-maximal effect between 10(-6) M and 10(-5) M. Thus, Daflon 500 mg behaves as a potent protective agent against inflammatory disorders. These properties may explain, at least in part, the clinical activity of Daflon 500 mg and justify its therapeutic use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203787

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  8 in total

Review 1.  [Systemic therapy of chronic venous diseases].

Authors:  S Reich; P Altmeyer; M Stücker
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

Review 2.  Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  The effect of purified micronized flavonoid fraction on the healing of anastomoses in the colon in rats.

Authors:  Aydin Inan; Meral Sen; Cemile Koca; Ayhan Akpinar; Cenap Dener
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Formation of 8-iso-PGF(2alpha) and thromboxane A(2) by stimulation with several activators of phospholipase A(2) in the isolated human umbilical vein.

Authors:  W Sametz; K Hummer; M Butter; R Wintersteiger; H Juan
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients.

Authors:  Sherine Maher Rizk; Nagwa Ali Sabri
Journal:  Saudi Pharm J       Date:  2009-08-07       Impact factor: 4.330

6.  Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney.

Authors:  Naveen Tirkey; Sangeeta Pilkhwal; Anurag Kuhad; Kanwaljit Chopra
Journal:  BMC Pharmacol       Date:  2005-01-31

7.  Diosmin reduces calcium oxalate deposition and tissue degeneration in nephrolithiasis in rats: a stereological study.

Authors:  Ali Noorafshan; Saied Karbalay-Doust; Fatemeh Karimi
Journal:  Korean J Urol       Date:  2013-04-16

8.  Antihyperalgesic Effect of Hesperidin Improves with Diosmin in Experimental Neuropathic Pain.

Authors:  Azucena I Carballo-Villalobos; María-Eva González-Trujano; Francisco Pellicer; Francisco J López-Muñoz
Journal:  Biomed Res Int       Date:  2016-09-08       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.